Breast Cancer: Novel Histological and Molecular Markers for Diagnosis, Prognosis, Therapeutic Prediction, and Drug Resistance

Guest Editors:

Dr. Maurizio Di Bonito
Pathology Unit, "Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli", Naples, Italy

Prof. Dr. Michelino De Laurentiis
Breast Medical Oncology Division, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Naples, Italy

Dr. Monica Cantile
Pathology Unit, Istituto Nazionale Tumori-Irccs-Fondazione G. Pascale, 80131 Naples, Italy

Deadline for manuscript submissions:
closed (15 August 2023)

Message from the Guest Editors

Dear colleagues,

Breast cancer includes a broad spectrum of diseases characterized by different molecular subtypes with specific gene signatures and distinct clinical outcomes. Moreover, one of the main problems in breast cancer therapeutic approaches is the establishment of an intrinsic or acquired resistance to treatment. Understanding these mechanisms and identifying the key molecules involved could offer a new scenario of biomarkers for the management of breast cancer patients.

This Special Issue entitled "Breast Cancer: Novel Histological and Molecular Markers for Diagnosis, Prognosis, Therapeutic Prediction, and Drug Resistance" aims to highlight novel diagnostic, prognostic, and predictive biomarkers that could improve breast cancer management and treatment.

Dr. Maurizio Di Bonito
Dr. Michelino De Laurentiis
Dr. Monica Cantile
Guest Editors

mdpi.com/si/59867

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us